Lizzano (IT)
{name}
{subtitle}
Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss
city
~41 mi. (Brindisi, Italy, +170 more cities)
facility
Novartis Investigative Site
biomarker
ER Negative, +4 more biomarkers
condition
Breast Carcinoma
drug
alpelisib, +1 more drug
drug type
chemotherapy, +1 more type
A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or Primary Advanced Endometrial Cancer
city
~51 mi. (Lecce, Italy, +144 more cities)
facility
GSK Investigational Site
condition
Endometrial Carcinoma
drug
carboplatin, +3 more drugs
drug type
chemotherapy, +2 more types
A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL (17P) or TP53 Mutation
city
~51 mi. (Lecce, Italy, +50 more cities)
facility
Asl Le-Ospedale "Vito Fazzi";U.O. Ematologia
condition
Chronic Lymphocytic Leukemia
drug
obinutuzumab, +1 more drug
drug type
chemotherapy, +1 more type
Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)
city
~79 mi. (Bari, Italy, +92 more cities)
facility
IRCCS Giovanni Paolo II. Ospedale Oncologico ( Site 0193)
condition
Bladder Urothelial Carcinoma
drug
chemotherapy, +2 more drugs
drug type
chemotherapy, +2 more types
Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants With Advanced/Metastatic Non-small Cell Lung Cancer
city
~79 mi. (Bari, Italy, +151 more cities)
facility
GSK Investigational Site
condition
Non-Small Cell Lung Carcinoma
drug
niraparib, +1 more drug
drug type
immunotherapy, +1 more type
A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors
city
~79 mi. (Bari, Italy, +41 more cities)
facility
A.O. U. Consorziale Policlinico di Bari; Oncologia Ginecologica
condition
Fallopian Tube Carcinoma, +2 more conditions
drug
ado-trastuzumab emtansine, +5 more drugs
drug type
chemotherapy, +2 more types